Frontlight ResearchEarly access
Active, not recruitingNo phase
Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation
Key facts
- Who runs it
- Shanghai Shenqi Medical Technology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 125 people enrolled
- Started
- 7 Mar 2022
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- SQ-Kyrin Transcatheter Mitral Valve Repair System
- Record updated
- 14 August 2023
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (35)Hide the full registry criteria
Who can take part
- Severe functional MR (FMR) ≥3+ as determined by transthoracic echocardiography (TTE)
- Note: Eligible TTE must be obtained at least 30 days after the subject has been stabilized on optimal therapy (including Guideline Directed Medical Therapy GDMT). In the judgment of the center's cardiac team, subjects have received adequate treatment according to applicable criteria, including treatment for coronary artery disease, left ventricular dysfunction, MR, and heart failure (e.g., with cardiac resynchronization therapy (CRT or CRT-D), implantable cardioverter-defibrillator (ICD) implantation, coronary revascularization, and stable GDMT (see Appendix III for the definition of GDMT)
- Age ≥ 18 years old, regardless of gender
- Cardiac function classification NYHA class II, III or ambulatory IV a
- At least one hospitalization for heart failure or subjects with high BNP > 150 pg/ml or high NT-proBNP > 600 pg/ml in the past 12 months
- Note: BNP or NT-proBNP must be obtained after the subject has stabilized on optimal therapy including Guideline Directed Medical Therapy (GDMT) at least 30 days. The patients can understand the purpose of the trial, voluntarily participate and sign an informed consent form, and are willing to undergo relevant tests and clinical follow-up
- Left ventricular end-systolic diameter (LVESD)≤70mm
- The MR beam mainly originates from the A2/P2 area
- Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>10mm
- Mitral valve effective orifice area (EOA) ≥ 4.0cm2
Who cannot take part
- Patients who are extremely frail and cannot tolerate general anesthesia surgery or is in the state of shock requiring circulatory support
- Received cardiac pacemaker therapy or cardiac resynchronization therapy (CRT, CRT-D) or implanted cardioverter-defibrillator (ICD) implantation therapy within 30 days
- History of mitral valve surgery
- Patients with infective endocarditis or suggestive of active infection
- Complicated with severe untreated coronary artery disease
- Patients with pulmonary hypertension (pulmonary systolic blood pressure>70mmHg)
- Patients with definite coagulation disorders and severe coagulation system diseases
- Patients with stroke or transient cerebral ischemic attack within 30 days
- Patients with other valve disease requiring surgery or interventional therapy
- Patients with severe macrovascular disease requiring surgical treatment
- Patients with inappropriate anatomical structures of the heart and valves indicated by imaging examinations
- Known allergy to contrast agents and nickel-titanium memory alloy products
- Patients with diseases that seriously affect the evaluation of treatment, such as patients with severe neurological lesions affecting cognitive ability, patients with malignant tumors, etc
- Left heart ejection fraction <20%
- Severe renal insufficiency (eGFR ≤ 25 mL/min) or requiring chronic renal replacement therapy
- patients with transthoracic echocardiographic evidence of moderate-severe to severe right ventricular dysfunction
- Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis
- Patients with clear contraindications to the use of anticoagulants
- Any intracardiac mass, left ventricular or atrial thrombus detected on transthoracic echocardiography
- Severe tricuspid TR
- Severe symptomatic carotid stenosis (>70% on ultrasonography) or carotid stenting within 30 days
- <Resting systolic blood pressure 90 mmHg or >160 mmHg
- Patient life expectancy < 12 months
- Patients with severe thoracic deformity
- Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. in patients with moderate-severe (3 +) or severe (4 +) functional MR (functional MR) who still have symptoms after full treatment.
The group in the trial
- SQ-Kyrin TMVr SystemTreatment being tested
Transcatheter edge-to-edge mitral valve repair using SQ-Kyrin TMVr System.
Treatment: SQ-Kyrin Transcatheter Mitral Valve Repair System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Single Arm Clinical Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in Patients With Moderate-severe or Severe Functional MR (FMR)
- Publications
- One-Year Outcomes of Novel Transcatheter Edge-to-Edge Mitral Repair System in Patients With Functional Mitral Regurgitation.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025
- Record updated
- 14 August 2023